Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Adverse Drug Reaction
82%
Drug
74%
Dipeptidyl Carboxypeptidase Inhibitor
47%
Incidence
46%
Methylphenidate
44%
Infection
40%
Antiinfective Agent
35%
Aldosterone
30%
Renin
30%
Lung Cancer
28%
Reslizumab
28%
Hypokalemia
28%
Drug-Drug Interaction
28%
Metformin
28%
Clozapine
28%
Anaphylaxis
28%
Chlorhexidine
28%
Metoprolol
28%
Hyponatremia
28%
Diuretic Agent
28%
Progression Free Survival
26%
Overall Survival
26%
Flucloxacillin
24%
Phenprocoumon
23%
Serine Proteinase
22%
Angiotensin Converting Enzyme 2
22%
Cohort Study
18%
Symptom
17%
Coughing
17%
Enalapril
17%
Captopril
17%
Apolipoprotein E
17%
Anticoagulant Agent
17%
Asthma
15%
Complication
14%
Potassium
14%
Pharmacoepidemiology
14%
Programmed Cell Death
14%
Non Small Cell Lung Cancer
14%
Programmed Death 1 Ligand 1
14%
Antidiabetic Agent
13%
Antihypertensive Agent
12%
Hemoglobin A1c
12%
Nivolumab
12%
Attention Deficit Disorder
12%
Death
12%
Angiotensin
11%
Vitamin K Group
11%
Cancer Registry
11%
Medicine and Dentistry
Patient
85%
Therapeutic Procedure
61%
Hospital
45%
Drug
32%
Chemotherapeutic Agent
32%
Infection
28%
Anaphylaxis
28%
Hypokalemia
28%
Chlorhexidine
28%
Outpatient
28%
Diuretic Agent
28%
Hyponatremia
28%
Man
28%
Woman
28%
Antimicrobial Therapy
24%
Flucloxacillin
24%
Drug Therapy
24%
Pharmacogenetics
23%
Adverse Event
22%
Adverse Drug Reaction
20%
Supplementation
17%
Vitamin D
17%
Patient with Hypertension
14%
Severe Asthma
14%
Incidence
14%
Colecalciferol
14%
Potassium
14%
Antibiotic Therapy
10%
Complication
10%
Inpatient
10%
Drug Administration Route
10%
Sunitinib
10%
Pazopanib
10%
Kidney Metastasis
10%
Urinary System
9%
Catheterization
9%
Drug Response
9%
Gene
9%
Cystoscopy
9%
Follow up
8%
Randomized Controlled Trial
8%
Side Effect
8%
Evaluation Study
8%
Progression Free Survival
7%
Overall Survival
7%
Female
7%
Eosinophilic
7%
Antibiotics
7%
Biological Product
7%
Antiinfective Agent
7%
Nursing and Health Professions
Patient
33%
Woman
33%
Chlorhexidine
28%
Anaphylaxis
28%
Odds Ratio
28%
Adverse Event
28%
Bradycardia
28%
Body Mass
28%
Control
23%
Man
21%
Heart Rate
21%
Dipeptidyl Carboxypeptidase Inhibitor
19%
Case-Control Study
19%
Vitamin D
17%
Supplementation
17%
Time
16%
Male
14%
Colecalciferol
14%
Female
14%
General Practitioner
14%
Blood Level
10%
Physician
10%
Consultation
9%
Cystoscopy
9%
Urethral Catheterization
9%
Lubricating Agent
9%
Coughing
9%
Captopril
9%
Catheterization
9%
Tablet
7%
Electrocardiogram
7%
Gender Difference
7%
Sample
7%